Magnetar Financial LLC Acquires 15,328 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Magnetar Financial LLC increased its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 125.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,511 shares of the biopharmaceutical company’s stock after buying an additional 15,328 shares during the period. Magnetar Financial LLC owned about 0.06% of Theravance Biopharma worth $259,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of TBPH. Algert Global LLC bought a new position in Theravance Biopharma in the third quarter worth approximately $851,000. Quantbot Technologies LP purchased a new position in Theravance Biopharma in the third quarter worth $60,000. BNP Paribas Financial Markets grew its holdings in Theravance Biopharma by 88.9% in the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after purchasing an additional 143,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Theravance Biopharma by 29.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 3,827 shares during the last quarter. Finally, Martingale Asset Management L P grew its holdings in Theravance Biopharma by 14.4% in the third quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 6,870 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $13.75.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.39 on Monday. The firm has a market capitalization of $464.53 million, a PE ratio of -9.30 and a beta of 0.15. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.90. The company’s fifty day moving average price is $9.32 and its 200-day moving average price is $9.06.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The company had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.